Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9345959 | 0.86 | DGAT1 (0.46) | DGAT1KCNN4ALDH1A1TSHRSRC | |
| SCHEMBL28296434 | 0.79 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL17281569 | 0.77 | DGAT1 (0.39) | DGAT1KCNN4ALDH1A1TSHRCA2 | |
| SCHEMBL18630822 | 0.77 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL18630824 | 0.77 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL4427911 | 0.76 | — | — | |
| SCHEMBL21393608 | 0.76 | KCNN4 (0.38) | DGAT1KCNN4ALDH1A1TSHRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL28075338 | 0.76 | KCNN4 (0.38) | DGAT1KCNN4ALDH1A1TSHRPTPN1 | |
| SCHEMBL20564537 | 0.75 | DGAT1 (0.38) | DGAT1KCNN4ALDH1A1TSHRPTPN1 | |
| SCHEMBL135961 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111635312-A | Synthesis method of (E) -2-fluoroalkyl-3-butenoate compound | 安阳师范学院 | 2020-09-08 | — | — | CN | claimed |
| CN-111635312-B | Synthesis method of (E) -2-fluoroalkyl-3-butenoate compound | 安阳师范学院 | 2023-02-21 | — | — | CN | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110627718-B | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2022-10-04 | — | — | CN | disclosed |
| US-20220227696-A1 | Multifunctional Fluorinated Compound, Fluorinated Polymers Made from the Compound, and Related Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2022-07-21 | — | — | US | disclosed |
| EP-3980433-A1 | MULTIFUNCTIONAL FLUORINATED COMPOUND, FLUORINATED POLYMERS MADE FROM THE COMPOUND, AND RELATED METHODS | 3M Innovative Properties Company (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-113906038-A | Multifunctional fluorinated compounds, fluorinated polymers made therefrom, and related methods | 3M创新有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020245724-A1 | MULTIFUNCTIONAL FLUORINATED COMPOUND, FLUORINATED POLYMERS MADE FROM THE COMPOUND, AND RELATED METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| CN-111635312-A | Synthesis method of (E) -2-fluoroalkyl-3-butenoate compound | 安阳师范学院 | 2020-09-08 | — | — | CN | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2155716-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | Pfizer Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| EP-0334966-B1 | PROCESS FOR SYNTHESIZING OPTICALLY ACTIVE COMPOUNDS | NGK INSULATORS LTD (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0334966-A1 | PROCESS FOR SYNTHESIZING OPTICALLY ACTIVE COMPOUNDS | NGK INSULATORS, LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | DGAT1 4831/4885KCNN4 1234/4885ALDH1A1 3777/4885 |
| US-20220227696-A1 | Multifunctional Fluorinated Compound, Fluorinated Polymers Made from the Compound, and Related Methods | NR1H2, NR1H3, NR1I2 | DGAT1 1655/4885KCNN4 855/4885ALDH1A1 2744/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | DGAT1 4831/4885KCNN4 1234/4885ALDH1A1 3777/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | DGAT1 4831/4885KCNN4 1234/4885ALDH1A1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.